Cargando…
Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives
With the development of microbiology and metabolomics, the relationship between the intestinal microbiome and intestinal diseases has been revealed. Fecal microbiota transplantation (FMT), as a new treatment method, can affect the course of many chronic diseases such as metabolic syndrome, malignant...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254144/ https://www.ncbi.nlm.nih.gov/pubmed/35949351 http://dx.doi.org/10.3748/wjg.v28.i23.2546 |
_version_ | 1784740630895788032 |
---|---|
author | Zheng, Lie Ji, Yong-Yi Wen, Xin-Li Duan, Sheng-Lei |
author_facet | Zheng, Lie Ji, Yong-Yi Wen, Xin-Li Duan, Sheng-Lei |
author_sort | Zheng, Lie |
collection | PubMed |
description | With the development of microbiology and metabolomics, the relationship between the intestinal microbiome and intestinal diseases has been revealed. Fecal microbiota transplantation (FMT), as a new treatment method, can affect the course of many chronic diseases such as metabolic syndrome, malignant tumor, autoimmune disease and nervous system disease. Although the mechanism of action of FMT is now well understood, there is some controversy in metabolic diseases, so its clinical application may be limited. Microflora transplantation is recommended by clinical medical guidelines and consensus for the treatment of recurrent or refractory Clostridium difficile infection, and has been gradually promoted for the treatment of other intestinal and extraintestinal diseases. However, the initial results are varied, suggesting that the heterogeneity of the donor stools may affect the efficacy of FMT. The success of FMT depends on the microbial diversity and composition of donor feces. Therefore, clinical trials may fail due to the selection of ineffective donors, and not to faulty indication selection for FMT. A new understanding is that FMT not only improves insulin sensitivity, but may also alter the natural course of type 1 diabetes by modulating autoimmunity. In this review, we focus on the main mechanisms and deficiencies of FMT, and explore the optimal design of FMT research, especially in the field of cardiometabolic diseases. |
format | Online Article Text |
id | pubmed-9254144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-92541442022-08-09 Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives Zheng, Lie Ji, Yong-Yi Wen, Xin-Li Duan, Sheng-Lei World J Gastroenterol Review With the development of microbiology and metabolomics, the relationship between the intestinal microbiome and intestinal diseases has been revealed. Fecal microbiota transplantation (FMT), as a new treatment method, can affect the course of many chronic diseases such as metabolic syndrome, malignant tumor, autoimmune disease and nervous system disease. Although the mechanism of action of FMT is now well understood, there is some controversy in metabolic diseases, so its clinical application may be limited. Microflora transplantation is recommended by clinical medical guidelines and consensus for the treatment of recurrent or refractory Clostridium difficile infection, and has been gradually promoted for the treatment of other intestinal and extraintestinal diseases. However, the initial results are varied, suggesting that the heterogeneity of the donor stools may affect the efficacy of FMT. The success of FMT depends on the microbial diversity and composition of donor feces. Therefore, clinical trials may fail due to the selection of ineffective donors, and not to faulty indication selection for FMT. A new understanding is that FMT not only improves insulin sensitivity, but may also alter the natural course of type 1 diabetes by modulating autoimmunity. In this review, we focus on the main mechanisms and deficiencies of FMT, and explore the optimal design of FMT research, especially in the field of cardiometabolic diseases. Baishideng Publishing Group Inc 2022-06-21 2022-06-21 /pmc/articles/PMC9254144/ /pubmed/35949351 http://dx.doi.org/10.3748/wjg.v28.i23.2546 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Zheng, Lie Ji, Yong-Yi Wen, Xin-Li Duan, Sheng-Lei Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives |
title | Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives |
title_full | Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives |
title_fullStr | Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives |
title_full_unstemmed | Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives |
title_short | Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives |
title_sort | fecal microbiota transplantation in the metabolic diseases: current status and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254144/ https://www.ncbi.nlm.nih.gov/pubmed/35949351 http://dx.doi.org/10.3748/wjg.v28.i23.2546 |
work_keys_str_mv | AT zhenglie fecalmicrobiotatransplantationinthemetabolicdiseasescurrentstatusandperspectives AT jiyongyi fecalmicrobiotatransplantationinthemetabolicdiseasescurrentstatusandperspectives AT wenxinli fecalmicrobiotatransplantationinthemetabolicdiseasescurrentstatusandperspectives AT duanshenglei fecalmicrobiotatransplantationinthemetabolicdiseasescurrentstatusandperspectives |